Brief: Docmorris AG Sees 2024 Adjusted EBITDA Between CHF 0 Million And Minus CHF 35 Million (Including E-Prescriptions)

DocMorris AG

21/03/2024 06:02

March 21 (Reuters) - DOCMORRIS AG  DOCM.S :
    * SIGNIFICANT EARNINGS IMPROVEMENT IN 2023; E-PRESCRIPTION
IS
STANDARD IN GERMANY
    * REVENUE AND EARNINGS TARGETS FOR 2023 ACHIEVED
    * IN MEDIUM TERM, AN ADJUSTED EBITDA MARGIN OF 8 PER CENT
REMAINS
TARGET
    * CAPITAL EXPENDITURE OF CHF 30 MILLION TO CHF 40 MILLION
EXPECTED
FY24
    * OUTLOOK 2024: CAPITAL EXPENDITURE OF CHF 30 MILLION TO CHF
40
MILLION
    * AN IMPROVEMENT IN ADJUSTED EBITDA TO BETWEEN CHF 0 MILLION
AND
MINUS CHF 35 MILLION (INCLUDING E-PRESCRIPTIONS) EXPECTED FY24
    * AN INCREASE OF MORE THAN 10 PER CENT IN EXTERNAL REVENUE
(INCLUDING E-PRESCRIPTIONS) EPXECTED FY24
    * EQUITY RATIO INCREASED A SUBSTANTIAL 17.8 PERCENTAGE
POINTS
YEAR-ON-YEAR TO 49.7 PER CENT AT END OF 2023

Source text for Eikon:  ID:nEQ6ttqQBa 
Further company coverage:  DOCM.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))